EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities

Meng Li, Suping Tang, Peng Yang, Hao Zhou

Frontiers in Oncology · 15.07.2026 · 16

DOI: 10.3389/fonc.2026.1713277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 15.07.2026. Verfasst von Meng Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy resistance and relapse remain major obstacles in the treatment of lymphoid malignancies. While the cancer stem cell (CSC) hypothesis has long served as a conceptual framework for understanding chemoresistance, evidence for its direct applicability in lymphoid malignancies is still limited. More recently, drug-tolerant persister (DTP) cells have emerged as an important model for exploring resistance mechanisms, offering complementary perspectives beyond the CSC paradigm. In this review, we summarize recent advances in the study of DTP cells in lymphoid malignancies, including their progression to drug-tolerant expanded persister (DTEP) cells. We discuss experimental models and methodological approaches for investigating DTP cells, as well as the underlying mechanisms of persistence and resistance, which encompass gene-regulatory changes, cell surface remodeling, and immune evasion strategies. Finally, we highlight potential therapeutic avenues such as targeting glycosylation-related pathways, exploiting immunotherapeutic glycopeptide targets, and implementing rational combination regimens. By integrating insights from DTP biology, this review aims to broaden current theories to therapy resistance in lymphoid malignancies and inform the development of innovative treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

cancer stem cellchemotherapy resistancedrug-tolerant expanded persisterdrug-tolerant persisterlymphoid malignancies

Autor:innen und Institutionen

  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, M., Tang, S., Yang, P., & Zhou, H. (2026). Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1713277

Vancouver

Li M, Tang S, Yang P, Zhou H. Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1713277

BibTeX
@article{Li2026,
  author = {Li, Meng and Tang, Suping and Yang, Peng and Zhou, Hao},
  title = {Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1713277}
}
Kostenlos starten →